Venture Capital

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

The Raine Group hires Credit Suisse veteran Anthony Kontoleon, signaling a major push to dominate TMT advisory ahead of an anticipated tech boom.

NorthX Biologics and Demeetra have partnered to offer a streamlined, royalty-free path from gene to GMP, tackling key bottlenecks for biotech startups.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

Public market giant Seligman Investments launches a venture arm with a seasoned team to invest in the foundational tech of tomorrow's economy.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

With a $60M Series A, Chamber Cardio is using AI and risk-sharing to move cardiology to a value-based model, aiming to fix America's costliest disease.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.